@article{6eeb569f91344799ac423762a90517ec,
title = "In Reply—Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome",
author = "Silber, {Michael H.} and Becker, {Philip M.} and Buchfuhrer, {Mark J.} and Earley, {Christopher J.} and Ondo, {William G.} and Walters, {Arthur S.} and Winkelman, {John W.}",
note = "Funding Information: Potential Competing Interests: Dr Silber receives royalties from UpToDate and payment for development of educational presentations from the American Academy of Sleep Medicine and American Academy of Neurology. Dr Buchfuhrer receives consultancy fees from Xenoport; receives payment for lectures including service on speakers bureaus from UCB Pharma, Arbor Pharmaceuticals, and Xenoport; owns stock/stock options in Sensory Medical. Dr Earley receives grants from Luitpold Pharmaceuticals and honorarium from the American Academy of Sleep Medicine. Dr Ondo receives grants from Luitpold Pharmaceuticals and payment for lectures including service on speakers bureaus from UCB Pharma. Dr Walters receives grants from Mundipharma, Arbor Pharmaceuticals, National Institutes of Health, UCB Pharma, and Xenoport. Dr Winkelman receives consultancy fees from Merck and Flex Pharma and grants from Restless Legs Syndrome Foundation, Luitpold Pharmaceuticals, NeuroMetrix, National Institute of Mental Health, and UCB Pharma; he is an employee of Massachusetts General Hospital. ",
year = "2018",
month = jul,
doi = "10.1016/j.mayocp.2018.03.021",
language = "English (US)",
volume = "93",
pages = "955--956",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Ltd",
number = "7",
}